Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Grows By 10.2%

Cardiff Oncology, Inc. (NASDAQ:CRDF) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 10,450,000 shares, a growth of 10.2% from the January 15th total of 9,480,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is presently 5.0 days.

Cardiff Oncology Price Performance

Shares of NASDAQ:CRDF opened at $4.29 on Tuesday. The business has a fifty day moving average price of $4.01 and a 200-day moving average price of $3.10. The company has a market capitalization of $219.35 million, a PE ratio of -4.56 and a beta of 1.77. Cardiff Oncology has a 1-year low of $1.65 and a 1-year high of $6.42.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HC Wainwright reduced their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Piper Sandler raised their target price on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday, December 13th.

Insider Buying and Selling at Cardiff Oncology

In related news, Director Gary W. Pace bought 350,115 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average price of $2.60 per share, with a total value of $910,299.00. Following the purchase, the director now owns 1,047,876 shares of the company’s stock, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Cardiff Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of CRDF. BNP Paribas Financial Markets bought a new position in shares of Cardiff Oncology during the fourth quarter valued at $25,000. ProShare Advisors LLC purchased a new position in Cardiff Oncology in the 4th quarter worth about $50,000. Raymond James Financial Inc. bought a new position in Cardiff Oncology during the 4th quarter valued at about $56,000. Voya Investment Management LLC purchased a new stake in shares of Cardiff Oncology during the 4th quarter valued at about $57,000. Finally, Caxton Corp bought a new stake in shares of Cardiff Oncology in the fourth quarter worth approximately $58,000. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.